Semaglutide
Also known as: Ozempic, Wegovy, Semaglutid, Rybelsus, Sema, GLP-1
Weekly GLP-1 agonist approved for diabetes and obesity — highly effective for fat loss, with the central caveat that a substantial share of the weight lost is lean mass.
Substance family
Gut hormone analogues that suppress appetite. Highly effective for fat loss, with the consistent caveat that a substantial share of the weight lost is lean mass unless protein and training compensate.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Obesity (Wegovy schedule)
MedicalDose
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg / week
Frequency
1× / week, subcutaneous
Cycle length
Each step held for 4 weeks before increasing
The stepwise titrationtitrationAdjusting a dose stepwise against a measured result rather than setting it in advance. is not caution for its own sake — it is what keeps gastrointestinal side effects manageable. Skipping steps is the most common reason people abandon the substance.
Type 2 diabetes (Ozempic schedule)
MedicalDose
0.25 → 0.5 → 1.0 mg / week
Frequency
1× / week, subcutaneous
Cycle length
Each step held for 4 weeks
Lower target dose than the obesity indication, since the goal is glycaemic control rather than maximum weight loss.
Diet phase in a bodybuilding context
IntermediateDose
0.25–1.0 mg / week
Frequency
1× / week, subcutaneous
Cycle length
8–16 weeks
Doses in this context usually stay well below the obesity maximum. The goal is appetite control in a deficit, not maximum weight loss — higher doses drive food intake so low that protein targets become hard to hit.
Off-season appetite control
IntermediateDose
0.25–0.5 mg / week
Frequency
1× / week, subcutaneous
Cycle length
Varies
Low doses are often enough to blunt appetite without meaningfully cutting into training performance.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Loss of lean mass — up to 40% of the weight lost can be muscle
Countermeasure
The most important point in a bodybuilding context. Keep protein high (roughly 2–2.5 g per kg of body weight), maintain resistance training throughout, and keep the deficit moderate. Because the substance suppresses appetite so effectively, protein must be planned deliberately rather than eaten by feel.
Problem
Nausea, vomiting, constipation, especially when increasing the dose
Countermeasure
Follow the 4-week titrationtitrationAdjusting a dose stepwise against a measured result rather than setting it in advance. steps rather than rushing them. Smaller meals, less fat and less alcohol during the adjustment phase. If a step is poorly tolerated, hold it longer instead of pushing to the next.
Problem
Delayed gastric emptying (gastroparesis)
Countermeasure
Documented and in rare cases persistent. Severe, ongoing vomiting or abdominal pain needs medical assessment. Relevant before any procedure requiring anaesthesia — inform the anaesthetist, since a full stomach is a genuine aspiration risk.
Problem
Dehydration and reduced training performance
Countermeasure
Lower food intake also means less fluid and fewer electrolytes. Drink deliberately, keep sodium and potassium adequate; sudden drops in strength are often a hydration problem rather than a muscle problem.
Problem
Rapid weight regain after stopping
Countermeasure
Appetite returns when the substance is discontinued. Plan the exit deliberately: taper the dose down and establish eating habits during use rather than relying on the substance to hold the result.
Problem
Uncertain product quality on the grey market
Countermeasure
Compounded and grey-market versions vary considerably in content. Only sources with an independent analysis certificate; reconstitute sterile, store refrigerated and follow the labelled shelf life.
Overview
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, for obesity. It has become the most widely known substance in this class and has changed how weight loss is approached medically.
In the bodybuilding context, it is used in diet phases and for off-season appetite control. Its effect on food intake is genuinely powerful — which is precisely where the main problem lies, because appetite suppression alone does not distinguish between fat and muscle.
Mechanism of Action
GLP-1 is a hormone released by the gut after eating. It stimulates insulin release, inhibits glucagon, slows gastric emptying and signals satiety to the brain. Semaglutide mimics this hormone but is modified so it is not broken down within minutes — hence the weekly injection.
The practical effect is a marked reduction in appetite and food intake. Slowed gastric emptying reinforces the feeling of fullness and is at the same time the source of most gastrointestinal side effects.
For anyone training, one consequence deserves particular attention. Studies on GLP-1 agonists consistently show that a considerable share of the weight lost is lean mass — figures around forty percent appear repeatedly. This is not a peculiarity of the drug; a large deficit without adequate protein and training stimulus produces the same result. But the substance makes it easy to eat far too little without noticing, because the usual hunger signal that would correct it is absent.
Typical Context
In a bodybuilding context, doses generally stay well below those used for obesity. A quarter to one milligram a week is often enough to make a deficit manageable, while the higher obesity doses suppress intake so strongly that protein targets become difficult to reach.
The titration schedule matters more than it appears. Each step is held for four weeks, not out of excessive caution, but because gastrointestinal side effects scale with how quickly the dose rises. Most people who abandon semaglutide do so because they moved up too fast, not because the substance was fundamentally intolerable.
Discontinuation deserves planning. Appetite returns, and with it the weight, unless eating habits were established during the treatment period. The substance buys time and makes a deficit tolerable — it does not replace the behaviour that has to hold the result afterwards.
Side Effects & Risks
- Loss of lean mass alongside fat, particularly with an aggressive deficit
- Nausea, vomiting, constipation or diarrhoea, especially when increasing the dose
- Delayed gastric emptying, in rare cases persistent
- Dehydration and electrolyte imbalance through reduced intake
- Reduced training performance, particularly at higher doses
- Rapid weight regain after stopping
- Gallstones with rapid weight loss
- Rarely: pancreatitis
Blood Work & Monitoring
- HbA1c and fasting glucose — particularly relevant with pre-existing insulin resistance
- Lipid profile (LDL, HDL, triglycerides) — usually improves with weight loss
- Liver values (ALT, AST, GGT) — fatty liver often improves
- Electrolytes (sodium, potassium) — reduced intake makes shifts more likely
- Body composition — the key measurement here; scale weight alone hides muscle loss
Harm-Reduction Notes
- Protein is the deciding factor: plan roughly 2–2.5 g per kg of body weight deliberately, because appetite will not remind you
- Keep resistance training running throughout — it is the main protection against muscle loss
- Hold each titration step for four weeks; rushing is the main cause of intolerance
- Inform the anaesthetist before any procedure — delayed gastric emptying is an aspiration risk
- Track body composition rather than scale weight alone
- Plan the exit: taper down and build eating habits during use
- Grey-market products vary widely in content; insist on an analysis certificate
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Prescription-only medicineApproved for defined indications; use outside them is off-label. |
| EU / UK | Prescription-only medicineApproved for defined indications. |
| Canada / Australia | Prescription-only medicine |
| Parts of Asia, Latin America & Middle East | Pharmacy availability variesSeveral countries dispense it without prescription in practice. Rules and enforcement differ and change. |
| Competitive sport | Check the current WADA listSome substances in this class are prohibited, others are not. |